Nature Medicine
- 12, 1294 - 1300 (2006)
Published online: 22 October 2006; | doi:10.1038/nm1491
Genomic signatures to guide the use of chemotherapeuticsAnil Potti, Holly K Dressman, Andrea Bild, Richard F Riedel, Gina Chan, Robyn Sayer, Janiel Cragun, Hope Cottrill, Michael J Kelley, Rebecca Petersen, David Harpole, Jeffrey Marks, Andrew Berchuck, Geoffrey S Ginsburg, Phillip Febbo, Johnathan Lancaster & Joseph R Nevins Supplementary Fig. 1 (pdf 230K)
A patient-derived docetaxel gene expression signature predicts response to docetaxel in cancer cell lines Supplementary Fig. 2 (pdf 380K)
Development of gene expression signatures that predict sensitivity to a panel of commonly used chemotherapeutic drugs Supplementary Fig. 3 (pdf 185K)
Specificity of chemotherapy response predictors Supplementary Fig. 4 (pdf 280K)
Relationships in predicted probability of response to chemotherapies in breast (Panel A), lung (Panel B) and ovarian cancer (Panel C) Supplementary Fig. 5 (pdf 370K)
Integrating prediction of oncogenic pathway deregulation with chemotherapeutic sensitivity Supplementary Table 1 (pdf 450K)
The genes constituting the individual chemosensitivity predictors developed on the NCI-60 cell line panel and the genes constituting the PI3 kinase pathway predictor Supplementary Table 2 (pdf 50K)
A summary of the chemotherapy response predictors: validations in cell line and patient data sets Supplementary Table 3 (pdf 50K)
An enrichment analysis showing that a genomic-guided response prediction increases the probability of a clinical response in the different data sets studied; a comparison of this data to previously reported predictors of response Supplementary Methods (pdf 375K)
| 
